Gossamer Bio, Inc. (GOSS) Upgraded to Outperform at Leerink Partners

Market Context

Gossamer Bio, Inc. operates in the Healthcare sector. The stock currently trades at $0.20 with a market capitalization of $824.3M. The stock has declined 88.8% over the past 52 weeks.

Analyst upgrades often act as catalysts for near-term price movement, particularly when they come from major firms with significant institutional following. Leerink Partners's upgrade suggests their analysts see improving fundamentals, a more favorable risk-reward profile, or upcoming catalysts that could drive the stock higher.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Gossamer Bio, Inc.

Among the 10 most recent ratings: 6 Buy, 2 Hold, 2 Sell.

Date	Firm	Rating	Price Target
Jul 28, 2026	Leerink Partners	Outperform	N/A
Jul 27, 2026	HC Wainwright & Co.	Buy	N/A
Jun 25, 2026	HC Wainwright & Co.	Buy	N/A
May 26, 2026	HC Wainwright & Co.	Buy	N/A
May 19, 2026	Barclays	Underweight	N/A

Related Tools: Analyst Ratings Dashboard | View GOSS Stock Page